A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Lenacapavir' was developed by Gilead Sciences, a research-based biopharmaceutical company in the US, as a pre-exposure prophylaxis (PrEP) medication to prevent infection in people at risk of exposure ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the ...

Dayton & Montgomery County Public Health hosted its ninth annual “Rocking our Red Pumps” event on Friday to recognize ...

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

HIV prevention medication ‘could one day be a yearly jab’ – study suggests - Yearly doses could reduce barriers people face ...

There is almost complete halt of HIV Prevention interventions that were fully funded by PEPFAR. This includes DREAMS programme targeting vulnerable adolescent girls and young women, orphans and ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...